Quest Diagnostics Management
Management criteria checks 4/4
Quest Diagnostics' CEO is Jim Davis, appointed in Nov 2022, has a tenure of 1.5 years. total yearly compensation is $12.67M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 0.067% of the company’s shares, worth $10.34M. The average tenure of the management team and the board of directors is 5.2 years and 7.5 years respectively.
Key information
Jim Davis
Chief executive officer
US$12.7m
Total compensation
| CEO salary percentage | 9.3% |
| CEO tenure | 1.5yrs |
| CEO ownership | 0.07% |
| Management average tenure | 5.2yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26
We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt
Apr 23Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares
Apr 02Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year
Mar 15Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75
Feb 06Quest Diagnostics: Post-COVID Normalization Pretty Much Done
Feb 05Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 11Why We're Not Concerned About Quest Diagnostics Incorporated's (NYSE:DGX) Share Price
Dec 24Quest Diagnostics: Market Overreaction Creates Investment Opportunity
Dec 08Is There Now An Opportunity In Quest Diagnostics Incorporated (NYSE:DGX)?
Dec 06Quest Diagnostics' (NYSE:DGX) Returns Have Hit A Wall
Nov 18Quest Diagnostics: Moving Past Covid
Oct 25Here's Why Quest Diagnostics (NYSE:DGX) Can Manage Its Debt Responsibly
Sep 25What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Sep 04Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues
Aug 15Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
Aug 13Quest Diagnostics Incorporated (NYSE:DGX) Shares Could Be 46% Below Their Intrinsic Value Estimate
Jul 11Is Quest Diagnostics (NYSE:DGX) A Risky Investment?
Jun 09Quest Diagnostics: Healthier Diagnosis
May 30Is It Time To Consider Buying Quest Diagnostics Incorporated (NYSE:DGX)?
May 24Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
May 09An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 24% Undervalued
Mar 22What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Feb 19Why Quest Diagnostics Isn't A 'Buy', My Oh My
Feb 14Quest Diagnostics' (NYSE:DGX) Upcoming Dividend Will Be Larger Than Last Year's
Feb 05Quest Diagnostics Q4 2022 Earnings Preview
Feb 01Quest Diagnostics' unit Pack Health to expand Alabama facility
Jan 17Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 17Returns On Capital Are Showing Encouraging Signs At Quest Diagnostics (NYSE:DGX)
Jan 03An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 46% Undervalued
Dec 04Quest Diagnostics declares $0.66 dividend
Nov 14Is Now The Time To Look At Buying Quest Diagnostics Incorporated (NYSE:DGX)?
Nov 06Decode Health, Quest to collaborate to improve biomarker discovery for drug discovery
Oct 18Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Oct 06Quest Diagnostics to acquire select assets of Summa Health
Oct 05Quest Diagnostics: The Market Is Overlooking Long-Term Prospects
Sep 15Quest Diagnostics: Valuation Looks Good As Covid Testing Demand Tapers
Sep 09Returns Are Gaining Momentum At Quest Diagnostics (NYSE:DGX)
Aug 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$842m |
| Dec 31 2023 | US$13m | US$1m | US$850m |
| Sep 30 2023 | n/a | n/a | US$759m |
| Jun 30 2023 | n/a | n/a | US$790m |
| Mar 31 2023 | n/a | n/a | US$789m |
| Dec 31 2022 | US$12m | US$806k | US$942m |
| Sep 30 2022 | n/a | n/a | US$1b |
| Jun 30 2022 | n/a | n/a | US$1b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$4m | US$625k | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$2b |
| Dec 31 2020 | US$4m | US$577k | US$1b |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | n/a | n/a | US$749m |
| Mar 31 2020 | n/a | n/a | US$771m |
| Dec 31 2019 | US$3m | US$590k | US$835m |
| Sep 30 2019 | n/a | n/a | US$709m |
| Jun 30 2019 | n/a | n/a | US$707m |
| Mar 31 2019 | n/a | n/a | US$720m |
| Dec 31 2018 | US$3m | US$590k | US$733m |
| Sep 30 2018 | n/a | n/a | US$860m |
| Jun 30 2018 | n/a | n/a | US$808m |
| Mar 31 2018 | n/a | n/a | US$782m |
| Dec 31 2017 | US$3m | US$590k | US$769m |
Compensation vs Market: Jim's total compensation ($USD12.67M) is about average for companies of similar size in the US market ($USD13.53M).
Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.
CEO
Jim Davis (60 yo)
1.5yrs
Tenure
US$12,673,834
Compensation
Mr. James E. Davis, also known as Jim, serves as Chief Executive Officer and President at Quest Diagnostics Incorporated since November 1, 2022 and serves as its Director since November 2022. He served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 1.5yrs | US$12.67m | 0.067% $ 10.3m | |
| Executive VP & CFO | 1.8yrs | US$3.98m | 0.019% $ 3.0m | |
| Senior VP & General Counsel | 24.8yrs | US$2.25m | 0.035% $ 5.3m | |
| Executive Vice President of Regional Businesses | no data | US$3.16m | 0.058% $ 9.0m | |
| Senior Vice President of Clinical Solutions | 1.8yrs | US$2.02m | 0.015% $ 2.4m | |
| Senior VP | 5.1yrs | no data | 0.032% $ 4.9m | |
| Senior VP and Chief Information & Digital Officer | 5.3yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior VP & Chief Compliance Officer | 1.6yrs | no data | no data | |
| Senior VP & Chief Communications Officer | 27.5yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | 6.3yrs | no data | no data | |
| Senior Vice President of Strategy | 8.3yrs | no data | no data |
5.2yrs
Average Tenure
60yo
Average Age
Experienced Management: DGX's management team is seasoned and experienced (5.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 1.5yrs | US$12.67m | 0.067% $ 10.3m | |
| Independent Director | 10.3yrs | US$315.44k | 0.019% $ 2.9m | |
| Lead Independent Director | 12.4yrs | US$345.94k | no data | |
| Independent Director | 19.4yrs | US$342.12k | no data | |
| Independent Director | 27.3yrs | US$304.82k | 0.028% $ 4.3m | |
| Independent Director | 5.3yrs | US$312.33k | 0.0026% $ 396.0k | |
| Independent Director | 9.8yrs | US$314.44k | 0.015% $ 2.3m | |
| Independent Director | 4.2yrs | US$300.44k | no data | |
| Independent Director | 2.8yrs | US$300.44k | no data | |
| Independent Director | less than a year | no data | no data |
7.5yrs
Average Tenure
65.5yo
Average Age
Experienced Board: DGX's board of directors are considered experienced (7.5 years average tenure).